Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …

HER2 belongs to the human epidermal growth factor receptor tyrosine kinase family. Its
overexpression or hyperactivation is a leading cause for multiple types of cancers. HER2 …

Tumor suppressor p53 is inactivated by thousands of heterogeneous mutations in cancer,
but their individual druggability remains largely elusive. Here, we evaluated 800 common …

Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer
(NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth …

Personalized treatment strategies for cancer frequently rely on the detection of genetic
alterations which are determined by molecular biology assays. Historically, these processes …

Protein structure prediction is a longstanding issue crucial for identifying new drug targets
and providing a mechanistic understanding of protein functions. To enhance the progress in …

Lung cancer has been the most common and the leading cause of cancer deaths globally.
Besides clinicopathological observations and traditional molecular tests, the advent of …